LEXINGTON, Mass.--(BUSINESS WIRE)--May 16, 2013--
Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that data from a clinical study of PRM-151 in patients with idiopathic pulmonary fibrosis (IPF) will be presented in an oral presentation at the 2013 American Thoracic Society (ATS) International Conference being held from May 17-22, 2013, in Philadelphia, Penn. The clinical data to be presented are from a randomized, double-blind, placebo controlled Phase 1b multiple ascending dose study which examined safety and tolerability, as well as exploratory efficacy endpoints.
Read the entire article at:
For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com